DGAP-Adhoc

Fresenius SE & Co. KGaA: Fresenius Kabi to strengthen and diversify product portfolio by acquiring Akorn and Merck KGaA's biosimilars business - Seite 3

The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close in H2/2017.

The total investment in the biosimilars business will be mainly cash flow financed.

Implications of transactions on Group Financials


Fresenius confirms its 2020 earnings^** target range of EUR2.4 to 2.7 billion.

Both transactions combined are expected to be neutral to Group net income^** and EPS^** by 2020 and accretive from 2021 onwards. Before amortization and before integration costs, both transactions combined are projected to be neutral to Group net income^** and EPS^** by 2018 and to contribute positively from 2019 onwards.

Group net debt/EBITDA will temporarily increase to approximately 3.3 after closing of both transactions. The leverage ratio is expected to return to approximately 3.0 at the end of 2018.

Fresenius SE & Co. KGaA,

represented by Fresenius Management SE,

Board of Management

Bad Homburg v.d.H., 24 April 2017

* For a definition of Akorn's adjusted EBITDA please refer to Akorn's FY/16 press release as of 1 March 2017

** Net income attributable to shareholders of Fresenius SE & Co. KGaA

-------------------------------

For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures

For information regarding non-GAAP financial measures or adjusted figures derived from Akorn's public information, please see section "Non-GAAP Financial Measures" on Akorn's FY/16 press release using following link: http://investors.akorn.com/phoenix.zhtml?c=78132&p=irol-newsArticle&ID ...

-------------------------------

Contact:

Markus Georgi

Senior Vice President Investor Relations

T: [phone]

[e-mail]

-------------------------------

THIS RELEASE IS FOR INFORMATION PURPOSES ONLY.

This release does not constitute or form part of, and should not be construed as, any offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of Fresenius SE & Co. KGaA ("Fresenius") or any present or future member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities in Fresenius or any member of its group or any commitment whatsoever.